查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1265603

骨髓發育不良症候群(MDS)治療藥的全球市場

Myelodysplastic Syndrome (MDS) Drugs
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

骨髓發育不良症候群(MDS)治療藥的全球市場在2030年前將達到41億美元

在COVID-19後改變的商務環境中，2022年19億美元的骨髓發育不良症候群(MDS)治療藥的全球市場，在2030年前將達到41億美元的規模，在2022年～2030年預計將以年複合成長率以10.4％增長。本報告所分析之市場區隔之一的免疫調節藥將以年複合成長率10.8％增長，到分析期間結束時將達到27億美元。考慮疫情後的復甦，定影劑甲基化劑市場領域今後8年的年複合成長率將修正為5.5％。

美國市場估算為5億1,070萬美元，中國則將以年複合成長率16.7％增長

美國的骨髓發育不良症候群(MDS)治療藥市場在2022年估算為5億1,070萬美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為16.7％，在2030年前將達到11億美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以4.5％和8.8％的速度成長。在歐洲市場中，德國以年複合成長率6％成長。

調查對像企業範例

  • Amgen
  • BluePoint Laboratories
  • Celgene Corporation
  • Celgene Europe Limited
  • Johnson & Johnson
  • Lupin Ltd Corporation
  • Otsuka America Pharmaceutical Inc.
  • Reddy's Laboratories, Inc.
  • Sandoz
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Inc.
  • Takeda

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP22341

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Myelodysplastic Syndrome (MDS) Drugs Market to Reach $4.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Myelodysplastic Syndrome (MDS) Drugs estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$4.1 Billion by 2030, growing at aCAGR of 10.4% over the period 2022-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is projected to record 10.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hypomethylating Agents segment is readjusted to a revised 5.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $510.7 Million, While China is Forecast to Grow at 16.7% CAGR

The Myelodysplastic Syndrome (MDS) Drugs market in the U.S. is estimated at US$510.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 16.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 8.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6% CAGR.

Select Competitors (Total 34 Featured) -

  • Amgen
  • BluePoint Laboratories
  • Celgene Corporation
  • Celgene Europe Limited
  • Johnson & Johnson
  • Lupin Ltd Corporation
  • Otsuka America Pharmaceutical Inc.
  • Reddy's Laboratories, Inc.
  • Sandoz
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Inc.
  • Takeda

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • Myelodysplastic Syndrome (MDS) Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Immunomodulatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hypomethylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hypomethylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Hypomethylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Myelodysplastic Syndrome (MDS) Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • JAPAN
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • CHINA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: China 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • EUROPE
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • FRANCE
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: France 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • GERMANY
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • INDIA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: India 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030
  • AFRICA
    • Myelodysplastic Syndrome (MDS) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Myelodysplastic Syndrome (MDS) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Immunomodulatory Drugs, Hypomethylating Agents and Other Therapeutic Classes for the Years 2014, 2023 & 2030

IV. COMPETITION